CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.
A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
一名50岁日本男性，患五药难治性多发性骨髓瘤（MM），在接受idecabtagene vicleucel（ide-cel）治疗前被发现患有IIIa期心脏免疫球蛋白轻链淀粉样变性。经过慎重考虑并经医院伦理委员会批准后，开始ide-cel治疗。ide-cel输注后急性期出现3级细胞因子释放综合征和心房扑动，但在重症监护室通过支持治疗均耐受良好。患者在ide-cel输注后第60天达到严格完全缓解，第9个月达到心脏缓解，并于第133天因持续性心房扑动接受了导管消融。自ide-cel治疗以来，他已维持血液学和心脏缓解超过1年。本病例凸显了ide-cel在重度经治MM合并心脏淀粉样变性中控制疾病的有效性。
A 50-year-old Japanese man with penta-drug refractory multiple myeloma (MM) was found to have stage IIIa cardiac immunoglobulin light-chain amyloidosis before idecabtagene vicleucel (ide-cel) therapy. Ide-cel therapy was started after careful consideration and hospital ethics committee approval. Grade 3 cytokine release syndrome and atrial flutter occurred in the acute phase after ide-cel infusion, but these were well-tolerated with supportive care in the intensive care unit.
The patient achieved stringent complete response at day 60 and cardiac response at 9 months after ide-cel infusion with the addition of catheter ablation for sustained atrial flutter on day 133. He has maintained both hematological and cardiac remission for over 1 year since ide-cel therapy. This case highlights the effectiveness of ide-cel for disease control in heavily pretreated MM with cardiac amyloidosis.
MEMBER ACCOUNT
登录成功会直接打开下一页。
